Jose Serrano M.D., Ph.D.

Jose Serrano, M.D., Ph.D., serves as Project Scientist for the Drug-Induced Liver Injury Network (DILIN), providing scientific leadership and technical oversight for federally funded research initiatives focused on understanding and mitigating drug-induced liver injury. In this role, he plays a pivotal part in shaping the agency’s procurement strategy by defining scientific requirements, evaluating technical proposals, and ensuring alignment between research objectives and contracted services. His acquisitions primarily support advanced biomedical research, including clinical data analysis, biomarker validation, and translational studies in hepatotoxicology, bridging the gap between laboratory discovery and clinical application. Dr. Serrano collaborates with a diverse array of academic research institutions, contract research organizations, and specialized laboratories that deliver high-complexity scientific services. His partnerships are centered on entities capable of executing rigorous, multi-center clinical research protocols, advanced bioinformatics, and regulatory-compliant data management. While no single contractor dominates his portfolio, he consistently engages vendors with demonstrated expertise in pharmacovigilance, liver pathology, and clinical trial design, fostering long-term, performance-driven relationships grounded in scientific rigor and reproducibility. Dr. Serrano’s procurement activities reflect a strong preference for open competition, with 100% of acquisitions designated as non-set-aside. This reflects the specialized nature of DILIN’s research needs, which often require highly technical capabilities not commonly found among small or socioeconomically disadvantaged businesses. While he does not prioritize 8(a), HUBZone, or SDVOSB set-asides, his approach remains compliant with federal procurement regulations and emphasizes technical merit over socioeconomic categorization. His primary procurement focus lies within NAICS 541712—Research and Development in the Physical, Engineering, and Life Sciences—where he procures services in clinical pharmacology, molecular toxicology, and data analytics for rare disease phenotyping. His domain expertise spans hepatobiliary disease mechanisms, drug metabolism pathways, and clinical trial methodology, ensuring that all contracted efforts advance the scientific mission of DILIN with precision and integrity.